WASHINGTON, D.C. (January 19, 2006) – The Biotechnology Industry Organization (BIO) will sponsor its third annual BIO-Asia Partnering Conference Jan. 30-31, 2006, in Tokyo at the Grand Hyatt Tokyo.
BIO-Asia has grown 50 percent since its debut in 2004. It is an opportunity to meet and network with the world’s leading biotechnology and pharmaceutical companies and promising emerging drug development firms. BioCentury Publications, Mitsubishi UFJ Securities and Montgomery & Co. will be co-hosting and sponsoring this premier partnering event with support from the Japan BioIndustry Association (JBA).
“This conference is far and away the largest biotechnology-pharmaceutical partnering event in Asia,” said Morrie Ruffin, BIO’s executive vice president of capital formation and business development. To date, this year’s event has attracted over 375 participants from more than 200 international biotechnology and pharmaceutical companies representing Asia, North America, Europe, Africa and Australia.
This exclusive, customized partnering forum joins U.S., European and Pacific Rim drug development companies with Asian biotechnology and pharmaceutical companies interested in research collaborations and licensing agreements.
The conference format features private, pre-arranged one-on-one meetings between senior-level executives. Over the course of two days, more than 1,000 private meetings will be scheduled with countless networking opportunities.
Colin J. Reddrop, BPharm., Ph.D., senior vice president, global drug development, Japan and head of Japan R&D, AstraZeneca Pharmaceuticals LP, will deliver the luncheon keynote address at noon Monday, Jan. 30, 2006. Hiroshi Akimoto, Ph.D., managing director, Takeda Pharmaceutical Company Ltd., will deliver the luncheon keynote beginning at noon Tuesday, Jan. 31, 2006.
Plenary sessions will take up the topics of partnering and licensing trends on a global scale; challenges and opportunities in building an oncology company through partnerships and acquisitions; business models that best address the productivity gap from the venture capitalist point of view; and current approaches in the treatment of diabetes.
Media registration is complimentary. For more information visit directly www.bio.org/bioasia or contact email@example.com for assistance.
BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and 31 other nations. BIO members are involved in the research and development of healthcare, agricultural, industrial and environmental biotechnology products.